Methods Of Inhibiting Tumorigenesis In Colon Adenocarcinoma And Compositions Therefor

Abstract

Described herein are methods and compositions for the treatment of colon cancers.

What is claimed is: 
     
         1 . A pharmaceutical composition for treating a colon cancer-related disease, comprising:
 at least one miR gene product selected from the group consisting of anti-sense miR-20a, anti-sense miR-21, anti-sense miR-106a, anti-sense miR-181b, anti-sense miR-203 and combinations thereof;   wherein at least one of the anti-sense miR-20a, anti-sense miR-21, anti-sense miR-106a, anti-sense miR-181b and anti-sense miR-203 are present in a sufficient amount to bind to a corresponding miRNA in colon cancer cells, and to inhibit the expression of the corresponding miRNA in the colon cancer cells; and,   a pharmaceutically-acceptable carrier.   
     
     
         2 . The pharmaceutical composition of  claim 1 , wherein the miR gene product is anti-sense miR-21. 
     
     
         3 . The pharmaceutical composition of  claim 1 , wherein the colon cancer-related disease is adenocarcinoma. 
     
     
         4 . An agent that interferes with at least one colon cancer-related disease response signaling pathway, for the manufacture of a medicament for treating, preventing, reversing or limiting the severity of a colon cancer-related disease complication in an individual,
 wherein the agent comprises at least one miR gene product selected from the group consisting of anti-sense miR-20a, anti-sense miR-21, anti-sense miR-106a, anti-sense miR-181b, anti-sense miR-203 and combinations thereof.   
     
     
         5 . The agent of  claim 4 , wherein the at least one miR gene product is anti-sense miR-21. 
     
     
         6 . A method of treating or limiting the severity of a colon cancer-related disease complication in an individual in need thereof, comprising:
 administering to the individual at least on miRNA gene product that interferes with at least one colon cancer-related disease response cascade,   wherein the at least one miR gene product is anti-sense miR-21.   
     
     
         7 . An agent that interferes with at least one colon cancer-related disease response cascade, for the manufacture of a medicament for treating, reversing or limiting the severity of a colon cancer-related disease complication in an individual,
 wherein the agent comprises at least one miR gene product selected from the group consisting of anti-sense miR-20a, anti-sense miR-21, anti-sense miR-106a, anti-sense miR-181b, anti-sense miR-203 and combinations thereof.   
     
     
         8 . The agent of  claim 7 , wherein the at least one miR gene product is anti-sense miR-21.